Modified recombinant factor viii and von willebrand factor and methods of use
AssigneesBaxter Healthcare S.A., Baxter International Inc.
InventorsHans-Peter Schwarz, Peter Turecek
Life of this patent
Estimating the term…
Abstract
The present invention provides novel methods of increasing the survival of a coagulation protein by inhibiting the interaction with a clearance receptor. The invention also provides methods of preparing compositions that inhibit coagulation protein clearance receptors. Conjugated coagulation proteins, including compositions and formulations thereof, are also provided by the present invention.
Claims14
A method of increasing the survival of a coagulation protein by inhibiting the interaction with a clearance receptor, the method comprising the steps of:
- (a) modifying a coagulation protein with a water soluble polymer, and
- (b) administering to a mammal in need thereof a therapeutically effective amount of a composition comprising the modified coagulation factor;
- wherein the modification increases the survival of the protein in the blood circulation of a mammal.
A method of increasing the survival of Factor VIII by inhibiting the interaction with a clearance receptor, the method comprising the steps of:
- (a) modifying a binding protein of Factor VIII with a water soluble polymer, and
- (b) administering to a mammal in need thereof a therapeutically effective amount of a composition comprising the modified binding protein,
- wherein said binding protein is von Willebrand Factor.
14-33. (canceled)
Dependencies are inferred from the claim text.